JP4584534B2 - 胃食道逆流性疾患の治療のための材料 - Google Patents

胃食道逆流性疾患の治療のための材料 Download PDF

Info

Publication number
JP4584534B2
JP4584534B2 JP2002501422A JP2002501422A JP4584534B2 JP 4584534 B2 JP4584534 B2 JP 4584534B2 JP 2002501422 A JP2002501422 A JP 2002501422A JP 2002501422 A JP2002501422 A JP 2002501422A JP 4584534 B2 JP4584534 B2 JP 4584534B2
Authority
JP
Japan
Prior art keywords
methoxy
amino
chloro
alkyl
benzoylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002501422A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003535128A (ja
JP2003535128A5 (US06552046-20030422-C00019.png
Inventor
パスカル ドラズギャラ
ピーター ジー． ミルナー
ジュルグ フィスター
サイラス ベッカー
Original Assignee
アリックス セラピューティクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリックス セラピューティクス filed Critical アリックス セラピューティクス
Publication of JP2003535128A publication Critical patent/JP2003535128A/ja
Publication of JP2003535128A5 publication Critical patent/JP2003535128A5/ja
Application granted granted Critical
Publication of JP4584534B2 publication Critical patent/JP4584534B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2002501422A 2000-06-07 2001-06-07 胃食道逆流性疾患の治療のための材料 Expired - Fee Related JP4584534B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20992600P 2000-06-07 2000-06-07
US60/209,926 2000-06-07
PCT/US2001/018365 WO2001093849A2 (en) 2000-06-07 2001-06-07 Treatment of gastroesophageal reflux disease using piperidine derivatives

Publications (3)

Publication Number Publication Date
JP2003535128A JP2003535128A (ja) 2003-11-25
JP2003535128A5 JP2003535128A5 (US06552046-20030422-C00019.png) 2010-06-03
JP4584534B2 true JP4584534B2 (ja) 2010-11-24

Family

ID=22780902

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002501422A Expired - Fee Related JP4584534B2 (ja) 2000-06-07 2001-06-07 胃食道逆流性疾患の治療のための材料

Country Status (6)

Country Link
US (3) US6552046B2 (US06552046-20030422-C00019.png)
EP (1) EP1296684A2 (US06552046-20030422-C00019.png)
JP (1) JP4584534B2 (US06552046-20030422-C00019.png)
AU (2) AU2001275326C1 (US06552046-20030422-C00019.png)
CA (1) CA2410939C (US06552046-20030422-C00019.png)
WO (1) WO2001093849A2 (US06552046-20030422-C00019.png)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8287554B2 (en) * 1999-06-22 2012-10-16 Ethicon Endo-Surgery, Inc. Method and devices for tissue reconfiguration
US7846180B2 (en) 1999-06-22 2010-12-07 Ethicon Endo-Surgery, Inc. Tissue fixation devices and methods of fixing tissue
US6821285B2 (en) * 1999-06-22 2004-11-23 Ndo Surgical, Inc. Tissue reconfiguration
US6663639B1 (en) * 1999-06-22 2003-12-16 Ndo Surgical, Inc. Methods and devices for tissue reconfiguration
US6835200B2 (en) 1999-06-22 2004-12-28 Ndo Surgical. Inc. Method and devices for tissue reconfiguration
US7049326B2 (en) * 2000-05-12 2006-05-23 The University Of Toledo Method and compositions for temporarily incapacitating subjects
US6750238B1 (en) 2000-05-12 2004-06-15 The University Of Toledo Aralkyl ester soft drugs
AU2004268641A1 (en) * 2003-08-29 2005-03-10 Dynogen Pharmaceuticals, Inc. Compositions useful for treating gastrointestinal motility disorders
US7834010B2 (en) 2003-12-23 2010-11-16 Serodus As Modulators of peripheral 5-HT receptors
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
MXPA06007853A (es) 2004-01-07 2007-01-26 Aryx Therapeutics Compuestos estereoisomericos y metodos para el tratamiento de desordenes gastrointestinales y del sistema nervioso central.
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
US7326787B2 (en) * 2005-08-31 2008-02-05 Aryx Therapeutics, Inc. Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
WO2007149929A1 (en) * 2006-06-23 2007-12-27 Aryx Therapeutics, Inc. Piperidine derivatives for the treatment of gastrointestinal and cns disorders
KR100976063B1 (ko) * 2007-03-16 2010-08-17 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
US8852216B2 (en) 2007-03-23 2014-10-07 Ethicon Endo-Surgery, Inc. Tissue approximation methods
KR20100026641A (ko) * 2008-09-01 2010-03-10 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
ES2525515T3 (es) 2010-09-01 2014-12-23 Janssen Pharmaceutica, N.V. Antagonistas del receptor 5-HT2B
WO2013172239A1 (ja) * 2012-05-17 2013-11-21 Jsr株式会社 酸拡散制御剤、感放射線性樹脂組成物、レジストパターン形成方法、化合物及び化合物の製造方法
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
CN112816528B (zh) * 2021-02-01 2024-04-09 合肥艾创微电子科技有限公司 一种感知存储集成式仿生触觉纤维及其制备方法
CN112966411B (zh) * 2021-02-07 2022-05-24 华南理工大学 一种基于体代表单元应力的医疗植入件及制备方法与应用
CN113581374B (zh) * 2021-08-25 2023-01-10 杭州海斗量海洋仪器有限公司 一种用于防护监测设备的浮标
CN115935635B (zh) * 2022-11-29 2024-02-27 上海玫克生储能科技有限公司 基于电化学模型的锂电池路端电压计算方法、装置及介质

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE35550B1 (en) * 1970-09-03 1976-03-18 Wyeth John & Brother Ltd Amino-and acylamino-pyridine and -hydropyridine derivatives
GB1425706A (en) * 1972-06-30 1976-02-18 Wyeth John & Brother Ltd Piperidine derivatives
US5057525A (en) 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1317940C (en) * 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US5395832A (en) 1991-02-15 1995-03-07 Hokuriku Seiyaku Co., Ltd. Benzamide derivatives
TW213460B (US06552046-20030422-C00019.png) 1991-02-15 1993-09-21 Hokuriku Pharmaceutical
JP3104142B2 (ja) * 1991-02-15 2000-10-30 北陸製薬株式会社 ベンズアミド誘導体
IT1260485B (it) * 1992-05-29 1996-04-09 Procedimento e dispositivo per il trattamento dell'obesita' di un paziente
AU680453B2 (en) * 1992-11-05 1997-07-31 Smithkline Beecham Plc Piperidine derivatives as 5-HT4 receptor antagonists
JP3529102B2 (ja) * 1997-07-11 2004-05-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノート シヤツプ ５−ｈｔ３および５−ｈｔ４介在性障害に有用な（＋）−ノルシサプリド
JPH11292846A (ja) 1998-02-10 1999-10-26 Hokuriku Seiyaku Co Ltd ベンズアミド誘導体及びそれを含有する医薬
JP3398111B2 (ja) * 1999-02-04 2003-04-21 北陸製薬株式会社 ベンズアミド誘導体及びそれを含有する医薬
AR022338A1 (es) * 1999-02-04 2002-09-04 Hokuriku Pharmaceutical Un compuesto de benzamida, medicamento que lo contiene, y uso para la manufactura de un medicamento para el tratamiento o prevencion de una enfermedad digestiva o para mejorar la movilidad del tracto gastrointestinal.
DE19933926A1 (de) * 1999-07-20 2001-01-25 Boehringer Ingelheim Pharma Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders

Also Published As

Publication number Publication date
US6552046B2 (en) 2003-04-22
USRE42412E1 (en) 2011-05-31
WO2001093849A3 (en) 2003-01-30
AU2001275326C1 (en) 2006-09-21
JP2003535128A (ja) 2003-11-25
US20020025970A1 (en) 2002-02-28
CA2410939C (en) 2010-02-16
CA2410939A1 (en) 2001-12-13
WO2001093849A2 (en) 2001-12-13
US20030216387A1 (en) 2003-11-20
AU7532601A (en) 2001-12-17
EP1296684A2 (en) 2003-04-02
AU2001275326B2 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
JP4584534B2 (ja) 胃食道逆流性疾患の治療のための材料
AU2001275326A1 (en) Treatment of gastroesophageal reflux disease using piperidine derivatives
US20150238473A1 (en) Methods and compositions for treating infection
EP2680849A2 (en) 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
HRP20020177A2 (en) Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
CN1409634A (zh) 药物组合产品及其在治疗胃肠疾病中的应用
NZ530211A (en) D-threo methylphenidate substantially free of the L-threo form to treat fatigue, neurobehavioral slowing and other cogitative disorders exacerbated by treatments associated with cancer therapy
CN1065459A (zh) 哌啶衍生物及其制备方法和治疗应用
BG63190B1 (bg) Използване на оптически чист (+) норцисаприд за лечение на емезис и смущения на централната нервна система
JP2009515877A (ja) Ｃｎｓ障害を処置するための組成物および方法
WO2006118307A1 (ja) 疼痛治療薬
KR101980534B1 (ko) 도네페질 미리스틸옥시메틸에테르 또는 이의 약제학적으로 허용가능한 염
TW202023535A (zh) Dp拮抗劑
WO1996031470A1 (en) Novel heterocyclic compounds
JP2010513534A (ja) Ｍｔｐインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
US6593331B2 (en) Method for treatment of pain
WO2009011901A2 (en) Methods for promoting wakefulness
EP1097924A1 (en) 4-hydroxy-4-phenylpiperidine derivatives having -opioid agonist activity and pharmaceuticals containing the same
AU2006201053B2 (en) Materials and methods for the treatment of gastroesophageal reflux disease
WO1996031500A1 (en) Novel heterocyclic compounds
JP2012006869A (ja) ピリミジノン化合物およびその医薬用途
EP4353712A1 (en) New n-heteroarylbenzamides derivatives as flt3 inhibitors
WO1996031473A1 (en) Novel heterocyclic compounds
JP3113447B2 (ja) アミノカルボン酸誘導体、その製造方法および用途
WO2005016331A1 (ja) Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060328

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100118

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100408

A524 Written submission of copy of amendment under section 19 (pct)

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100408

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100804

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100902

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130910

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees